LU92717I2 - Éliglustat, éventuellement sous la forme d'un sel physiologiquement acceptable - Google Patents

Éliglustat, éventuellement sous la forme d'un sel physiologiquement acceptable Download PDF

Info

Publication number
LU92717I2
LU92717I2 LU92717C LU92717C LU92717I2 LU 92717 I2 LU92717 I2 LU 92717I2 LU 92717 C LU92717 C LU 92717C LU 92717 C LU92717 C LU 92717C LU 92717 I2 LU92717 I2 LU 92717I2
Authority
LU
Luxembourg
Prior art keywords
eliglustat
possibly
acceptable salt
physiologically acceptable
disclosed
Prior art date
Application number
LU92717C
Other languages
English (en)
French (fr)
Original Assignee
Genzyme Corp
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23182463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92717(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp, Univ Michigan filed Critical Genzyme Corp
Publication of LU92717I2 publication Critical patent/LU92717I2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Cosmetics (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
LU92717C 2001-07-16 2015-05-13 Éliglustat, éventuellement sous la forme d'un sel physiologiquement acceptable LU92717I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30581401P 2001-07-16 2001-07-16

Publications (1)

Publication Number Publication Date
LU92717I2 true LU92717I2 (fr) 2015-11-24

Family

ID=23182463

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92717C LU92717I2 (fr) 2001-07-16 2015-05-13 Éliglustat, éventuellement sous la forme d'un sel physiologiquement acceptable

Country Status (16)

Country Link
US (11) US6855830B2 (da)
EP (3) EP2266968B1 (da)
JP (6) JP5038582B2 (da)
AT (2) ATE554082T1 (da)
BE (1) BE2015C029I2 (da)
BR (3) BR122015016314B8 (da)
CA (1) CA2453978C (da)
CY (1) CY2015028I2 (da)
DK (3) DK1409467T3 (da)
ES (3) ES2395463T3 (da)
FR (1) FR15C0036I2 (da)
HK (2) HK1132267A1 (da)
IL (3) IL159905A0 (da)
LU (1) LU92717I2 (da)
PT (3) PT2266968E (da)
WO (1) WO2003008399A1 (da)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890949B1 (en) * 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
WO2002062777A2 (en) 2001-01-10 2002-08-15 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
PT2266968E (pt) 2001-07-16 2013-02-25 Genzyme Corp Síntese de udp-glucose: inibidores de n-acil esfingosinaglucosiltransferase
WO2003045928A1 (en) * 2001-11-26 2003-06-05 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) * 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
JP4195411B2 (ja) * 2004-04-12 2008-12-10 セイコーエプソン株式会社 有機エレクトロルミネッセンス装置の製造方法
JP2008519840A (ja) * 2004-11-10 2008-06-12 ジェンザイム・コーポレイション 糖尿病の処置方法
ATE549020T1 (de) * 2005-01-26 2012-03-15 Allergan Inc Pharmazeutische zusammensetzungen enthaltend 1- benzyl-1- hydroxy-2,3-diamino-propylamine, 3- benzyl-3 hydroxy-2-amino-propionsäureamide und verwandte verbindungen als analgetika
PL2032134T3 (pl) 2006-05-09 2015-11-30 Genzyme Corp Sposoby leczenia stłuszczeniowej choroby wątroby obejmujące hamowanie syntezy glikosfingolipidów
WO2008089403A2 (en) 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharides comprising an aminooxy group and conjugates thereof
US9314466B2 (en) 2007-03-06 2016-04-19 Allergan, Inc. Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
JP2010520299A (ja) * 2007-03-06 2010-06-10 アラーガン、インコーポレイテッド ３−アリール−３−ヒドロキシ−２−アミノ−プロピオン酸アミド、３−ヘテロアリール−３−ヒドロキシ−２−アミノ−プロピオン酸アミドおよび関連化合物を使用する認知障害の処置方法
US20140179925A1 (en) 2009-09-04 2014-06-26 Allergan, Inc. Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2008109285A1 (en) 2007-03-06 2008-09-12 Allergan, Inc. Methods for treating cognitive disorders
EP2594564B1 (en) * 2007-05-31 2016-09-28 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
RU2517345C9 (ru) * 2007-10-05 2014-08-20 Гензим Корпорейшн Способ лечения поликистозных заболеваний почек с помощью производных церамида
US8168631B2 (en) 2008-02-05 2012-05-01 Allergan, Inc. 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
KR101687039B1 (ko) 2008-10-03 2016-12-15 젠자임 코포레이션 2-아실아미노프로판올형 글루코실세라미드 합성효소 억제제
CN105879047A (zh) 2008-12-16 2016-08-24 建新公司 寡糖-蛋白缀合物
HUE029371T2 (en) * 2009-11-27 2017-02-28 Genzyme Corp GENZ 112638 For treatment of Gaucher or Fabry disease in combination therapy
US8880109B2 (en) 2010-04-16 2014-11-04 Kyocera Corporation Radio communication system, high-power base station, low-power base station, and communication control method
US20140186326A1 (en) 2011-04-22 2014-07-03 William Canfield Modified acid alpha glucosidase with accelerated processing
US8961959B2 (en) 2011-10-17 2015-02-24 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
EP2968268B1 (en) 2013-03-15 2020-07-29 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
AU2014321397C1 (en) 2013-09-20 2019-08-01 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
WO2015059679A1 (en) * 2013-10-25 2015-04-30 Dr. Reddy's Laboratories Limited Improved process for the preparation of eliglustat
EP3063141B1 (en) 2013-10-29 2018-02-28 BioMarin Pharmaceutical Inc. N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors
JP6749923B2 (ja) 2015-02-02 2020-09-02 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン グルコシルセラミドシンターゼ阻害剤及びそれを使用した治療方法
CN104557851B (zh) * 2015-02-10 2017-04-05 苏州明锐医药科技有限公司 依鲁司他的制备方法
WO2016166170A1 (en) 2015-04-14 2016-10-20 Sandoz Ag Crystalline eliglustat hydrochloride
WO2017068496A1 (en) * 2015-10-20 2017-04-27 Dr. Reddy' S Laboratories Limited Improved process for the preparation of eliglustat and its salts
CN105646442A (zh) * 2015-10-27 2016-06-08 北京凯莱天成医药科技有限公司 一种依利格鲁司他的制备方法
US20190142782A1 (en) 2016-04-11 2019-05-16 Spedding Research Solutions Inhibitors of glucosylceramide degradation in the treatment of diseases of the motor units
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
CN106967042B (zh) * 2017-03-21 2020-08-14 浙江奥翔药业股份有限公司 依利格鲁司他的合成方法及其中间体化合物
CN108822072B (zh) * 2017-04-11 2021-01-12 中国医学科学院药物研究所 一种制备伊力格鲁司他的方法
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
WO2018225085A1 (en) 2017-06-05 2018-12-13 Cipla Limited Stable solid dispersions of eliglustat hemitartrate
MX2020006272A (es) 2017-12-15 2020-09-14 Genzyme Corp Metodos para tratar la enfermedad de gaucher.
WO2019123476A1 (en) 2017-12-20 2019-06-27 Sarudbhava Formulations Private Limited Stable amorphous eliglustat premix and process for the preparation thereof
CN111217791B (zh) * 2018-11-27 2024-02-02 广东东阳光药业股份有限公司 依鲁司他中间体及其制备方法
US20220185788A1 (en) * 2019-03-22 2022-06-16 Piramal Pharma Limited An improved process for the preparation of eliglustat and its intermediate
WO2020193746A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival of patients suffering from melanoma
WO2021081141A1 (en) 2019-10-23 2021-04-29 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
WO2021214771A1 (en) 2020-04-23 2021-10-28 The Israel Institute of Biological Research (IIBR) Glucosylceramide synthase inhibitors for prevention and treatment of viral diseases
JP2023523454A (ja) 2020-04-28 2023-06-05 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン グルコシルセラミド合成酵素のピリジン阻害剤及びそれらを使用する治療方法
CN116120274A (zh) 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型
EP4201403A1 (en) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
JPH0416856A (ja) 1990-05-10 1992-01-21 Canon Inc 正帯電性非磁性トナー
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
WO1995005177A1 (fr) * 1993-08-13 1995-02-23 Seikagaku Corporation Remede contre les maladies nerveuses
PT742789E (pt) * 1994-02-02 2000-12-29 Liposome Co Inc Lipossomas e compostos farmaceuticamente activos e metodos para a sua utilizacao
CN1152907A (zh) * 1994-06-10 1997-06-25 生化学工业株式会社 2-酰胺基丙醇化合物及其药物组合物
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US5916911A (en) 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20030073680A1 (en) * 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6890949B1 (en) * 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) * 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
NO965193L (no) * 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP3993908B2 (ja) * 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5916802A (en) * 1997-02-19 1999-06-29 Fritz Berthold Device for measuring ATP
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
AU756008B2 (en) * 1998-07-27 2003-01-02 Johns Hopkins University, The Methods for treating conditions modulated by lactosylceramide
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) * 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
WO2002062777A2 (en) 2001-01-10 2002-08-15 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7148251B2 (en) * 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
PT2266968E (pt) 2001-07-16 2013-02-25 Genzyme Corp Síntese de udp-glucose: inibidores de n-acil esfingosinaglucosiltransferase
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
PL2032134T3 (pl) * 2006-05-09 2015-11-30 Genzyme Corp Sposoby leczenia stłuszczeniowej choroby wątroby obejmujące hamowanie syntezy glikosfingolipidów

Also Published As

Publication number Publication date
DK1409467T3 (da) 2012-07-16
JP2013136618A (ja) 2013-07-11
US20050222244A1 (en) 2005-10-06
ES2395463T3 (es) 2013-02-15
DK2266968T3 (da) 2013-04-08
HK1153733A1 (da) 2012-04-05
EP2067775A1 (en) 2009-06-10
ATE554082T1 (de) 2012-05-15
BR122015016314B8 (pt) 2021-05-25
IL159905A (en) 2009-05-04
US6855830B2 (en) 2005-02-15
US7265228B2 (en) 2007-09-04
ES2395122T3 (es) 2013-02-08
ES2395463T4 (es) 2013-02-12
US8779163B2 (en) 2014-07-15
US8138353B2 (en) 2012-03-20
EP2067775B1 (en) 2012-04-25
ES2399323T3 (es) 2013-03-27
US9546161B2 (en) 2017-01-17
US20030050299A1 (en) 2003-03-13
BRPI0211379B1 (pt) 2018-02-14
PT2266968E (pt) 2013-02-25
CY2015028I1 (el) 2016-07-27
JP6182254B2 (ja) 2017-08-16
JP2005502635A (ja) 2005-01-27
US20050009872A1 (en) 2005-01-13
US20120296088A1 (en) 2012-11-22
BR122015016313B1 (pt) 2019-04-16
DK2067775T3 (da) 2012-07-16
JP2005255686A (ja) 2005-09-22
BR122015016314B1 (pt) 2019-04-16
JP2017075151A (ja) 2017-04-20
JP4708073B2 (ja) 2011-06-22
CA2453978C (en) 2011-10-11
IL159905A0 (en) 2004-06-20
US20170334888A1 (en) 2017-11-23
BR122015016313B8 (pt) 2021-05-25
PT2067775E (pt) 2012-07-16
CA2453978A1 (en) 2003-01-30
US7763738B2 (en) 2010-07-27
FR15C0036I2 (fr) 2016-05-27
JP5038582B2 (ja) 2012-10-03
US7196205B2 (en) 2007-03-27
CY2015028I2 (el) 2016-07-27
US20110003987A1 (en) 2011-01-06
JP2015180656A (ja) 2015-10-15
EP2266968B1 (en) 2013-01-09
US20070203223A1 (en) 2007-08-30
BRPI0211379B8 (pt) 2021-05-25
US20190322649A1 (en) 2019-10-24
EP2266968A2 (en) 2010-12-29
US7615573B2 (en) 2009-11-10
PT1409467E (pt) 2012-10-24
EP1409467B1 (en) 2012-04-18
JP2010095546A (ja) 2010-04-30
WO2003008399A1 (en) 2003-01-30
EP1409467A1 (en) 2004-04-21
US20150148534A1 (en) 2015-05-28
IL193244A0 (en) 2009-02-11
BE2015C029I2 (da) 2021-07-19
ATE555102T1 (de) 2012-05-15
US20210171507A1 (en) 2021-06-10
US20080058514A1 (en) 2008-03-06
HK1132267A1 (en) 2010-02-19
EP2266968A3 (en) 2011-05-18
BR0211379A (pt) 2004-08-17
JP5227348B2 (ja) 2013-07-03
FR15C0036I1 (da) 2015-06-26

Similar Documents

Publication Publication Date Title
LU92717I2 (fr) Éliglustat, éventuellement sous la forme d'un sel physiologiquement acceptable
LTPA2016013I1 (lt) 2-okso-1-pirolidino dariniai, jų gamybos būdas ir jų panaudojimas
LU92407I2 (fr) Afatinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable, y compris le sel dimaléate
MX9203346A (es) (+)-1-(3-dimetilaminopropil)-1-(4'-fluorfenil)-1,3-dihidro-sobenofuran -5-carbonitrilo y sus sales de adicion de acido no toxicas farmaceuticamente utiles.
ATE211732T1 (de) N-benzylpiperidin- und tetrahydropyridin-derivate
EP1276480A4 (en) PROCESS FOR THE MANUFACTURE OF RACEMIC BUPIVACAIN ENANTIOMERS, PHARMACEUTICAL COMPOSITIONS OF BUPIVACAINE, THESE PHARMACEUTICAL COMPOSITIONS OF BUPIVACAINE FORMULATED ON ITS FREE BASIS OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND THE USE THEREOF
HK1078580A1 (en) Antitumoral analogs of lamellarins
NO178397C (no) Substituerte 1,2,3,4-tetrahydrocyklopent[bÅindoler, 1,2,3,3a,4,8a-heksahydrocyklopent[bÅindoler og beslektede forbindelser, mellomprodukter og deres bruk som medikamenter
ATE294783T1 (de) Salze des 3-(2-(4-(4-(amino-imino-methyl)-phenyl)-4-methy -2,5-dioxo-imidazolidin-1-yl)- acetylamino)-3-phenyl-propionsäure-ethylesters
ITMI982857A0 (it) Processo per la sintesi di 5-(a-idrossialchil)benzo[1,3]diossoli
NO20004545D0 (no) FremgangsmÕte for fremstilling av (R)-<alfa>-(2,3- dimetoksyfenyl)-1-[2-(4-fluorofenyl)etyl]-4-piperidinmetanol
MXPA03006057A (es) Proceso para preparar (+) trans-4-p-fluorofenil -3 hidroximetil.
SE9701438D0 (sv) A new process
FI953994A (fi) Menetelmä (-)-N-metyyli-N-(4-(4-fenyyli-4-asetyyliaminopiperidiini-1-yl)-2-(3,4-diklorofenyyli)butyyli)bentsamidi ja sen farmaseuttisesti hyväksyttäviä suoloja
FR2699074B1 (fr) Procédé d'obtention d'un médicament se présentant sous la forme d'un produit comprimé pouvant être avalé, sucé, croqué, délité.
NO20030876D0 (no) Fremgangsmåte for racemisering av 1-benzyl-4-(4-fluorfenyl)-3- hydroksymetyl-1,2,3,6-tetrahydropyridin for bruk som mellomprodukt i syntese avparoxetin
HK1053791A1 (zh) 外消旋布比卡因對映體的製備方法，左旋布比卡因藥物組合物，自由碱基形式配方的左旋布比卡因藥物組合物或者其藥學上可接受的鹽以及自由碱基形式配方的左旋布比卡因藥物組合物的用途
ITTO990685A0 (it) Procedimento per la smaltatura a caldo dell'oro bianco.
ITVR20020007U1 (it) Capo d'abbigliamento, particolarmente per karting
DZ2767A1 (fr) Procédé pour la synthèse d'intermédiaires chloropurine.
BG106700A (en) Sodium 2-(4,6-dimethylpyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl) ethoxy-3,3-diphenylpropionate and use thereof as endothelin antagonist